MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
about
Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementNatural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerPhenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cellsRomidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.Phase I trial of a new schedule of romidepsin in patients with advanced cancers.Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.Evading apoptosis in cancer.Romidepsin for the treatment of non-Hodgkin's lymphoma.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonThe discovery and development of romidepsin for the treatment of T-cell lymphoma.Sézary syndrome: old enigmas, new targets.Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.Getting a GRP on histone deacetylase inhibitor selectivity.Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors.Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway.A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.Single-cell heterogeneity in Sézary syndrome
P2860
Q27024076-5DE20F13-CEB3-4424-84F0-C0378CD76B84Q28073020-D6EA8E78-8173-4A9A-A1F6-41E7A26F401CQ28396209-9816346B-E589-4795-9AAB-63AAD87AF9FBQ30936712-9AE81287-D0F5-4DF4-AD5A-862DB0239F01Q33983255-7B628230-C348-4845-8BC0-974FCEF76C62Q36027160-D7CE2E99-C990-4FF5-A25A-9E7D836CD0F9Q36140634-56A24E41-7663-40A5-B177-6EAF1E7405B7Q36283075-CDAAA3C5-FCED-4394-899D-23649F6BF661Q36470196-14C78ACC-9BA0-40CD-9CEA-C7C2FF8B8838Q37295663-52377BBE-F060-488C-9BC2-3A9010B18C62Q37505528-2722BEB2-A571-46B5-8C9C-A4F6B9633B3CQ37667088-62B95882-CC74-4976-845A-71BF90B775FDQ37684405-C3B4EA6F-F415-4D22-AF79-9340B2A44A6DQ38130013-5C9B7C6F-1A27-4F7B-9E60-00A7E1002DC8Q38455740-9EB47CB1-3F60-4E4A-975F-5661D5193493Q38478630-4CBA16E0-8419-414F-A181-770102E3A69FQ38713744-B0357D31-86B2-4B06-B5E0-C9003AADB662Q38772711-91C9EFA4-B99E-416E-9534-C9BCA639EA90Q38930297-5D74B9BF-01DD-4EB7-ABB6-C70DA9B60D55Q39021652-8E935736-9979-4CB3-A80E-991807A6AFBAQ39268578-836A5569-3376-4DE2-B99E-9D1004CE1593Q45808456-015EAD6C-B693-4F7F-BB81-505CB9065ED1Q46181428-4A3A6EC2-7CD6-4472-871C-5065487318E4Q47567993-FAC11230-85B5-4DCB-B475-15AB98E50D02Q48034709-09B83F9F-AB0C-4EF0-B68B-348538D94860Q49390599-EF1A49A7-ECB8-4AF0-A230-0A543AA148CEQ50117976-2B5F1541-CCFD-4E7C-91FE-9A22880A9F20Q51414305-A729F882-4B20-4DB9-8CFC-3C95DF75C0E0Q51484852-DF6C4ECA-6413-4D54-AB3B-AE78E2EC776AQ58712956-633ECA2B-D0C9-43DF-98BB-F309DD5C6858
P2860
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MAPK pathway activation leads ...... idepsin with an MEK inhibitor.
@en
type
label
MAPK pathway activation leads ...... idepsin with an MEK inhibitor.
@en
prefLabel
MAPK pathway activation leads ...... idepsin with an MEK inhibitor.
@en
P2093
P2860
P1433
P1476
MAPK pathway activation leads ...... idepsin with an MEK inhibitor.
@en
P2093
Andrew V Kossenkov
Arup R Chakraborty
Jean-Pierre Gillet
Julia Wilkerson
Louise C Showe
Michael M Gottesman
Nathan L Collie
Richard L Piekarz
Robert W Robey
Susan E Bates
P2860
P304
P356
10.1182/BLOOD-2012-08-449140
P407
P577
2013-03-26T00:00:00Z